{"favorite_id": 10198, "calc_type": "calculator", "dosing": false, "full_title_en": "PSA Doubling Time (PSADT) Calculator", "short_title_en": "PSA Doubling Time (PSADT) Calculator", "medium_description_en": "Calculates rate of PSA doubling in prostate cancer (correlates with survival).", "short_description_en": "PSA survival.", "before_use": "", "instructions_en": "<p>Use in patients with prostate cancer. Do not use for screening or diagnosis.</p>", "slug": "psa-doubling-time-psadt-calculator", "logic_language": "javascript", "md5": "5d99992b13d2165658d2e96ab5b70a6a", "cmeVersion": "10198.1", "cmeReleaseDate": "2022-10-07 00:00:00+00+00", "cmeEndDate": "2025-10-03 00:00:00+00+00", "cmeLastReviewed": "2022-10-03 00:00:00+00+00", "search_abbreviation_en": ["Psa", "psa doubling time", "psa velocity", "rate of rise of psa", "PSADT"], "seo": {"meta_description_en": "The PSA Doubling Time Calculator calculates rate of PSA doubling in prostate cancer (correlates with survival).", "keywords_en": "Psa, psa doubling time, psa velocity, rate of rise of psa, PSADT"}, "content": {"reviewer": {"expert_name": []}, "related_resources": {"videos": [], "sdm_tool": [], "teaching": [], "interests": [], "guidelines": [], "mdcalc_rating": [], "partner_contact": []}, "how_to_use": {"use_case_en": "<p><span id=\"docs-internal-guid-ab85dc0d-7fff-ee60-52d9-e77a14b36738\"></p>\n<ul>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Patients with prostate cancer who have undergone radical prostatectomy or definitive radiation therapy and have biochemical recurrence, defined as confirmed PSA &ge;0.2 ng/mL if radical prostatectomy&nbsp;or confirmed PSA rise of &ge;2 ng/mL above the nadir PSA level if radiation therapy.</p>\n</li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">PSADT has limited value in prostate cancer screening or diagnosis.</p>\n</li>\n</ul>", "pearls_pitfalls_en": "<p><span id=\"docs-internal-guid-db79d967-7fff-aa1c-8090-71cc7a21f3de\"></p>\n<ul>\n<li dir=\"ltr\">\n<p dir=\"ltr\">For patients with biochemical recurrence of prostate cancer, optimal PSADT calculation should include all PSA values of the individual within two years of initially documented PSA recurrence.</p>\n</li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Entering more values improves accuracy of estimation.</p>\n</li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Shorter PSADT reflects faster increase in PSA levels, while longer PSADT reflects a slower increase in PSA levels over time.</p>\n</li>\n</ul>", "why_use_en": "<p><span id=\"docs-internal-guid-d02779e6-7fff-004f-1fdd-2cae94b6c725\"></p>\n<ul>\n<li dir=\"ltr\">\n<p dir=\"ltr\">In patients with biochemical recurrence, PSADT:</p>\n</li>\n<ul>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Predicts risk of metastasis and risk of dying of prostate cancer when combined with other factors such as the <calculator id=\"2048\">Gleason Score</calculator> and length of time to biochemical recurrence.</p>\n</li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Helps identify patients more likely to develop clinically significant disease.</p>\n</li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Helps guide patient selection for salvage local therapy or androgen deprivation therapy.</p>\n</li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Helps guide utilization and timing of imaging studies.</p>\n</li>\n</ul>\n<li dir=\"ltr\">\n<p dir=\"ltr\">For patients with M0 castration resistant disease, PSADT helps guide patient selection for observation, second generation antiandrogen, androgen metabolism inhibitor, or other secondary hormone treatments.</p>\n</li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Used in assessment of eligibility for clinical trials.</p>\n</li>\n</ul>"}, "next_steps": {"advice_en": "<p><span id=\"docs-internal-guid-20c413c8-7fff-15e2-f927-e447ecf4e0b0\"></p>\n<ul>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Further management should be individualized based on age, comorbidities, life expectancy, patient preferences, and other relevant factors.</p>\n</li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">More detailed information can be found in the <a href=\"https://www.nccn.org/professionals/physician_gls/default.aspx#prostate\" target=\"_blank\">National Comprehensive Cancer Network (NCCN) Guidelines</a>.</p>\n</li>\n</ul>", "management_en": "", "critical_actions_en": ""}, "about": {"formula_en": "<p dir=\"ltr\">Prostate-specific antigen doubling time (PSADT) = ln(2) / x,</p>\n<p dir=\"ltr\">Where x = slope of the relationship between ln(PSA, ng/mL) and time of PSA measurement (i.e., ln(PSA<sub>n</sub>) - ln(PSA<sub>1</sub>) / time between PSA<sub>n</sub>&nbsp;and PSA<sub>1</sub>, where n refers to a measurement &gt;1)</p>", "more_info_en": "", "evidence_based_medicine_en": "<p><span id=\"docs-internal-guid-ab9b0aa0-7fff-41cd-72da-f76d609d80fc\">PSA doubling time&nbsp;(PSADT) has been studied as a survival measure in prostate cancer. A retrospective review of 304 prostate cancer patients with biochemical recurrence demonstrated that PSA doubling time, <calculator id=\"2048\">Gleason Score</calculator>, and length of time to biochemical recurrence following surgery were predictive of the risk for development of metastatic disease (<a href=\"https://jamanetwork.com/journals/jama/fullarticle/189741\" target=\"_blank\">Pound 1999</a>). Metastatic disease-free survival was the longest among those with Gleason Scores 5-7, length of time to biochemical recurrence &gt;2 years, and PSADT &gt;10 months.&nbsp;&nbsp;</p>", "references_list": {"Validation": [], "Outcomes": [], "Validations": [], "Original/Primary Reference": [{"text": "Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC. Natural history of progression after PSA elevation following radical prostatectomy. JAMA. 1999;281(17):1591-7.", "href": "https://jamanetwork.com/journals/jama/fullarticle/189741"}], "Other References": [{"text": "Patel A, Dorey F, Franklin J, Dekernion JB. Recurrence patterns after radical retropubic prostatectomy: clinical usefulness of prostate specific antigen doubling times and log slope prostate specific antigen. J Urol. 1997;158(4):1441-5.", "href": "https://www.ncbi.nlm.nih.gov/pubmed/9302139 "}, {"text": "NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer.", "href": "https://www.nccn.org/professionals/physician_gls/default.aspx#prostate"}], "Clinical Practice Guidelines": [], "Manufacturer Website": []}}, "creator": [{"qa_en": "", "approved": null, "name": "Dr. Charles R. Pound", "creator_info": {"deceased": null, "about_en": "<p>Charles R. Pound, MD, is the chief of urology in the department of surgery at the University of Mississippi Medical Center in Jackson, MS. He is also a professor of medicine at the University of Mississippi School of Medicine. Dr. Pound\u2019s primary research is focused on urologic malignancy including prostate, bladder, and renal cancers.</p>", "photo_en": "https://cdn-web-img.mdcalc.com/people/dr-charles-pound.jpg", "pubmedLink": "https://www.ncbi.nlm.nih.gov/pubmed/?term=Pound+CR%5BAuthor%5D"}}], "contributor": {"expert_name": [{"description": "", "firstName": "Nazli", "img": "", "lastName": "Dizman", "name": "Nazli Dizman, MD", "target": "", "signedCOI": true, "hasDisclosure": []}]}}, "input_schema": [{"conditionality": "", "default": null, "tips_en": "First (earliest) available PSA result", "optional": false, "name": "psa1", "type": "textbox", "label_en": "PSA<sub>1</sub>", "unit": "psa", "unit_info": {"name": "psa", "conversion": 1, "error_min": 0, "error_max": 10000, "warn_min": 0, "warn_max": 10000, "normal_max_si": 0, "normal_min_si": 0, "normal_min_us": 0, "units_si": "ng/mL", "units_us": "ng/mL"}}, {"conditionality": "", "default": null, "tips_en": "Second available PSA result", "optional": false, "name": "psa2", "type": "textbox", "label_en": "PSA<sub>2</sub>", "unit": "psa", "unit_info": {"name": "psa", "conversion": 1, "error_min": 0, "error_max": 10000, "warn_min": 0, "warn_max": 10000, "normal_max_si": 0, "normal_min_si": 0, "normal_min_us": 0, "units_si": "ng/mL", "units_us": "ng/mL"}}, {"conditionality": "", "default": null, "tips_en": "", "optional": false, "name": "time2", "type": "textbox", "label_en": "Time between PSA<sub>1</sub> and PSA<sub>2</sub> measurement", "unit": "psadt_days", "unit_info": {"name": "Days/Months", "conversion": 30.4375, "error_min": 0, "error_max": 5000, "warn_min": 0, "warn_max": 5000, "normal_max_si": 0, "normal_min_si": 0, "normal_min_us": 0, "units_si": "days", "units_us": "months"}}, {"type": "toggle", "name": "add1", "conditionality": "", "optional": false, "default": 0, "label_en": "Add another measurement", "show_points": false, "tips_en": "", "options": [{"label": "No", "value": 0}, {"label": "Yes", "value": 1}]}, {"conditionality": "add1>0", "default": null, "tips_en": "Third available PSA result", "optional": false, "name": "psa3", "type": "textbox", "label_en": "PSA<sub>3</sub>", "unit": "psa", "unit_info": {"name": "psa", "conversion": 1, "error_min": 0, "error_max": 10000, "warn_min": 0, "warn_max": 10000, "normal_max_si": 0, "normal_min_si": 0, "normal_min_us": 0, "units_si": "ng/mL", "units_us": "ng/mL"}}, {"conditionality": "add1>0", "default": null, "tips_en": "", "optional": false, "name": "time3", "type": "textbox", "label_en": "Time between PSA<sub>2</sub> and PSA<sub>3</sub> measurement", "unit": "psadt_days", "unit_info": {"name": "Days/Months", "conversion": 30.4375, "error_min": 0, "error_max": 5000, "warn_min": 0, "warn_max": 5000, "normal_max_si": 0, "normal_min_si": 0, "normal_min_us": 0, "units_si": "days", "units_us": "months"}}, {"type": "toggle", "name": "add2", "conditionality": "add1>0", "optional": false, "default": 0, "label_en": "Add another measurement", "show_points": false, "tips_en": "", "options": [{"label": "No", "value": 0}, {"label": "Yes", "value": 1}]}, {"conditionality": "add2>0", "default": null, "tips_en": "Fourth available PSA result", "optional": false, "name": "psa4", "type": "textbox", "label_en": "PSA<sub>4</sub>", "unit": "psa", "unit_info": {"name": "psa", "conversion": 1, "error_min": 0, "error_max": 10000, "warn_min": 0, "warn_max": 10000, "normal_max_si": 0, "normal_min_si": 0, "normal_min_us": 0, "units_si": "ng/mL", "units_us": "ng/mL"}}, {"conditionality": "add2>0", "default": null, "tips_en": "", "optional": false, "name": "time4", "type": "textbox", "label_en": "Time between PSA<sub>3</sub> and PSA<sub>4</sub> measurement", "unit": "psadt_days", "unit_info": {"name": "Days/Months", "conversion": 30.4375, "error_min": 0, "error_max": 5000, "warn_min": 0, "warn_max": 5000, "normal_max_si": 0, "normal_min_si": 0, "normal_min_us": 0, "units_si": "days", "units_us": "months"}}, {"type": "toggle", "name": "add3", "conditionality": "add2>0", "optional": false, "default": 0, "label_en": "Add another measurement", "show_points": false, "tips_en": "", "options": [{"label": "No", "value": 0}, {"label": "Yes", "value": 1}]}, {"conditionality": "add3>0", "default": null, "tips_en": "Fifth available PSA result", "optional": false, "name": "psa5", "type": "textbox", "label_en": "PSA<sub>5</sub>", "unit": "psa", "unit_info": {"name": "psa", "conversion": 1, "error_min": 0, "error_max": 10000, "warn_min": 0, "warn_max": 10000, "normal_max_si": 0, "normal_min_si": 0, "normal_min_us": 0, "units_si": "ng/mL", "units_us": "ng/mL"}}, {"conditionality": "add3>0", "default": null, "tips_en": "", "optional": false, "name": "time5", "type": "textbox", "label_en": "Time between PSA<sub>4</sub> and PSA<sub>5</sub> measurement", "unit": "psadt_days", "unit_info": {"name": "Days/Months", "conversion": 30.4375, "error_min": 0, "error_max": 5000, "warn_min": 0, "warn_max": 5000, "normal_max_si": 0, "normal_min_si": 0, "normal_min_us": 0, "units_si": "days", "units_us": "months"}}], "chief_complaint_en": ["Any/All"], "specialty_en": ["Hematology and Oncology", "Urology"], "purpose_en": ["Calculation", "Prognosis"], "system_en": ["Genitourinary", "Oncologic", "Reproductive", "Urinary"], "disease_en": ["Cancer", "Prostate Cancer"], "related_calcs": [{"calcId": 2049, "short_title_en": "D'Amico Classification", "slug": "damico-risk-classification-prostate-cancer"}, {"calcId": 2076, "short_title_en": "Prostate Tumor Volume", "slug": "prostate-tumor-volume-density"}, {"calcId": 10039, "short_title_en": "CASPAR Criteria for PsA", "slug": "caspar-criteria-psoriatic-arthritis"}]}